Summary: Blood-sugar levels were assessed before and after 200 applications of low-level laser therapy (LLLT) in 32 patients. The results were as follows: An average decrease of 1.54 mmol/lt in 70.5%; an average increase of 0.82 mmol/lt in 28%; and unchanged results in 1.5%. Longterm sugar HbA1c was reduced by an average of 1.23%. The most efficient application of LLLT was with the red intravascular laser using a frequency setting of 3323 Hz, the insulin frequency. Further studies are necessary to support these findings.
Author: Dr. Andreas Wirz-Ridolfi, MD, Surgeon (Foederatio Medicorum Helveticorum) and licensed Acupuncturist (Acupuncture and TCM ASA)
Translation: Translated from German by Duvan Hoffmann | English translation ©2021 Duvan Hoffmann
Publication: Originally published in German in the June 2008 edition (pages 61-65) of Schmerz & Akupunktur, Europäische Zeitschrift für Ganzheitliche Schmerztherapie und Akupunktur | Pain & Acupuncture: The European Magazine for Holistic Pain Therapy and Acupuncture co-published by MH Weber, Weber Medical GmbH. ISSN 1611-521x
Keywords: Low-level laser therapy, diabetes, insulin frequency, 3323 Hz, blood-sugar level reduction
Every year, diabetes kills nearly 4 million people worldwide — a death every 10 seconds. Two decades ago the number of diabetes cases was 30 million, a number which had jumped more than eight-fold to 246 million cases in 2006. Obesity is among the key factors paving the way to this medical catastrophe.
In Germany, for example, 75.4% of men, and 58.9% of women, are overweight (a Body Mass Index over 25). And, with increasing prosperity, even developing countries are facing a rapid increase in the disease. According to a study by the World Health Organization (WHO), 1.1 million people died of diabetes in 2005, 80% of which were in developing or emergent nations. And life expectancies for people with diabetes in such countries do not look good. In Mosambique, for example, people with diabetes rarely live a year beyond their diagnosis.
Not only the incidence of diabetes, but also its economic impact, is rapidly gaining concern. In Germany alone, according to WHO, there were 8 million people with diabetes in 2006 and 20% of the state insurance payouts are paid for the treatment of diabetes and the health complications that follow. Leading to a race for new therapeutic options. Numerous new therapeutic possibilities include insulin pump for Type 1, islet cell transplantation, autologous stem cell transplant, dietary capsaicin, injectable diabetes drug synthesized from gila monster saliva, monthly injection instead of capsules for Type 2, and possibly the newly discovered insulin frequency of 3323 Hz.
Dr. Frank Bahr, MD, former student, colleague and research partner of the late physician, Paul Nogier, and a leading contributor to contemporary Auricular Medicine, suggested that there must be a therapeutic medical laser frequency that resonates with the endocrinal pancreas point (also known as the insulin point) reflected on the ear at the level of points T10-T12 in the antihelical wall, at the transition from the upper third to the middle thrid of the wall (and corresponding to point TB-4 of the Triple Burner meridian in body acupuncture (Strittmatter 2011, p. 204). Using programmable lasers and various insulin samples (Insulatard and Mixtard produced by Novo Nordisk) my team and I arrived at the frequency of 3323 Hz. The finding requires additional systematic review. However, this (the method for this finding, its verification and discussion thereof), is beyond the scope of this article. For the study, the hypothesis was: Treatment using the insulin frequency, a frequency of 3323 Hz, may possibly lower blood-sugar levels of patients with diabetes.
To answer these this hypothesis, a series of 200 treatments was completed December 2006 through January 2008 at the Medi-China Clinic and Center for Traditional Chinese Medicine outside of Basel, Switzerland. 32 patients (13 women and 19 men) participated in the study: 16 patients with diabetes Type 2 in the treatment group, and 16 patients with normal blood sugar levels in the control group. Treatments were administered using the following clinical laser methods/equipment:
- Intravascular laser using Weberneedle® Endolaser system by Weber Medical GmbH (https://www.webermedical.com) — color red 632 nm, 1.5 MW, 20 minutes
- Intravascular laser system by Gasparyan/Romberg — color blue 430 nm
- Transcutaneous laser using Weberneedle® system
- Transcutaneous laser using LASERneedle® system by Ronbar AG
- Transcutaneous laser using the ternary laserblock from Modulas (some treatments were expanded with respective auricular or body acupunture)
Measurements of blood-sugar levels were completed before and after treatment, including the Hemoglobin A1c (HbA1c) average blood glucose levels, as follows:
- Capillary/arterial blood glucose levels using Free Style Lite by Abbott
- Venous plasma glucose levels using Reflotron® clinical chemistry system
- HbA1c through Medica Labormedizin, Wolfbachstrasse 17, CH-8032 Zürich (before and after each treatment series)
By definition, a fasting blood sugar over 6.1 mmol/liter or 126 mg/dl is considered in the range of pathology. The HbA1c ascertains the average blood-sugar levels of the last 6-10 weeks and should be in a range of 4-6%.
Methods & Applications
CIAM Editor’s note: Since the publication of his study, Dr. Wirz approached the Canadian Institute of Auricular Medicine (CIAM) in 2019 to help present the methods and applications from this study in a manner to support training. CIAM is developing training with the necessary pedagogy for integrative application across various practice settings. This will support the effort for a multi-clinic study as proposed in the conclusions of my paper. Interested clinicians are invited to contact CIAM for the full paper and intention of interest in joining the multi-clinic study.
Rates of change
- 141 of the 200 sets of blood-sugar level readings (70.5%) confirmed a reduction in blood-sugar levels
- 56 of the 200 sets of blood-sugar level readings (28%) confirmed an increase in blood-sugar levels
- In 3 sets of readings the values remained unchanged.
Levels of change
- The maximum reduction in blood-sugar level was 8.64 mmol/liter.
- The maximum increase in blood-sugar levels was 7.35 mmol/liter.
Average extent of change dependent on group
- When considering the change across both groups (diabetics and control) the average reduction of blood-sugar levels was 1.54 mmol/liter and the average increase was 0.82 mmol/liter
- However, when considering the readings of each group individually, the average reduction for diabetics was 1.48 mmol/liter, while only 0.5 mmol/liter in the control group; and the increase for the diabetics was 0.889 mmol/liter, and 0.61 mmol/liter in the control group
These results point the possibility that diabetics are much more responsive to the laser therapy. The HbA1c average blood glucose levels were reduced by 1.23% in 8 patients.
Initial results were promising enough that the use of intravascular laser therapy with the insulin frequency of 3323 Hz is now the method of choice in my clinic — and I cannot imagine my practice without it. Still, it is necessary to have further study — beyond the capacity of a pravate practice — with a clearer design, significantly large enough patient population, and statistical analyses, ideally a coordinated multi-clinic study that can support a breakthrough for this clinical approach.
The possibilities for frequency-based therapies (through the application of frequncy modulating lasers to trigger healing responses in place of pharmacological triggers) are fascinating and becoming aparent at
a time of increasing querulousness toward big pharma, they offer targeted and highly specific treatment — and show the promise of an economical healthcare approach without pharmacological side-effects.
For interested parties: Please contact the Canadian Institute of Auricular Medicine (CIAM) if you are interest in training or participation in furthering the work of this study through multi-clinic participation.
Conflict of Interest Statement: Although there is no conflict of interest disclosed by the author, it is noted that Weber Medical lasers are among the lasers used in the author’s practice and for this study. Weber Medical, GmbH, is a co-publisher of the Schmerz & Akupunktur publication in which this paper was first published.